News
Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an ...
Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...
14h
WISH-TV on MSNLilly breaks ground on $4.5 billion R&D facilityEli Lilly officials and Gov. Mike Braun break ground on the LEAP District's Lilly Medicine Foundry, a $4.5 billion project ...
Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of ...
In a career spanning four decades, Patricia Clarkson has amassed an impressive array of accolades, including three Emmys, a Golden Globe, and nominations for an Oscar and Tony Award. Now, in the film ...
Eli Lilly and Co. will break ground on its $4.5 billion Lilly Medicine Foundry in Lebanon, Indiana's LEAP Research and Innovation District. The foundry could bring in 400 highly skilled workers to ...
Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.
Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.
Eli Lilly & Co.’s shares fell 6% early Thursday after the drugmaker cut its full-year earnings outlook citing research costs ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results